Neoadjuvant T-VEC Improves Survival in Resectable Melanoma
Talimogene laherparepvec improved recurrence-free and overall survival.
Skin Cancer
Nonmelanoma Skin Cancers Larger Among Hispanic Patients
Mohs micrographic surgery defect sizes were 17% larger among Hispanic/Latino patients.
Skin Cancer App Fails to Identify Rare, Aggressive Cancers
The sensitivity and specificity for detecting malignancy was 79.4% and 37.7%, respectively.
Higher Rate of Treatment Discontinuation Seen in Real-World Patients With Melanoma
Relapse-free survival outcomes were similar between real-world and clinical trial patients.
Incidence of Keratinocyte Carcinoma Up From 2003 to 2017
The mortality rate of keratinocyte carcinoma was 1.8 times higher in men than women between 1998 and 2017.
Survival Up With Tebentafusp in Metastatic Uveal Melanoma
Tebentafusp bested investigator’s choice of therapy in patients with previously untreated, metastatic uveal melanoma.
Adjuvant Pembrolizumab Prolongs Relapse-Free Survival in Stage II Melanoma
Adjuvant pembrolizumab prolongs relapse-free survival, when compared with placebo, in patients with resected, stage II melanoma.
Oncolytic Therapy Adds No Survival Benefit to PD-1 Treated Advanced Melanoma
Median OS was not reached for the T-VEC plus pembrolizumab arm and 49.2 months for the placebo plus pembrolizumab arm.
Increased Risk of Cancers for Firefighters at WTC on 9/11
The firefighters had elevated standardized incidence ratios for prostate cancer and melanoma.
Pretreatment Found to Reduce Stages of Mohs Surgery for Basal Cell Carcinoma
A retrospective study evaluated the effect of 5% imiquimod prior to Mohs surgery in patients with basal cell carcinoma.
- Loading...
Loading...
Next post in Skin Cancer
Loading... 
Loading...